ORASURE TECHNOLOGIES INC. - COMMON STOCK

OraSure Technologies’ Subsidiary Diversigen Launches Metatranscriptomic Sequencing and Analysis Services for Gut Microbiome Samples

31 Mar 2022 06:05:00 By Nasdaq GlobeNewswire

OraSure Director Nancy Gagliano Selected to Serve as Interim Chief Executive Officer; Brings Extensive Diagnostics and Healthcare Leadership Experience to Role

22 Mar 2022 15:05:00 By Nasdaq GlobeNewswire

OraSure Technologies Reports 4Q21 Revenue of $63.6 Million; InteliSwab® Production Scales Up

23 Feb 2022 15:05:01 By Nasdaq GlobeNewswire

OraSure Technologies, Inc. 2021 Fourth Quarter Earnings Conference Call Wednesday, February 23, 2022, 5:00 p.m. ET

16 Feb 2022 15:05:01 By Nasdaq GlobeNewswire

InteliSwab® COVID-19 Rapid Tests Receive U.S. FDA Authorization for Pediatric Use and Company Launches New InteliSwab® Connect Reporting App

31 Jan 2022 06:05:00 By Nasdaq GlobeNewswire

OraSure Technologies, Inc. Expands HIV Oral Swab In-home Test into Europe

25 Jan 2022 06:05:00 By Nasdaq GlobeNewswire

InteliSwab® COVID-19 Rapid Tests Detect Omicron at Same Level as Other Variants

13 Jan 2022 15:05:00 By Nasdaq GlobeNewswire

OraSure Technologies Announces Actions to Enhance Stockholder Value

05 Jan 2022 06:05:00 By Nasdaq GlobeNewswire

OraSure Technologies Announces 2022 Annual Meeting Date

14 Dec 2021 06:05:00 By Nasdaq GlobeNewswire

OraSure Technologies Remains Committed to the Global Fight Against HIV 40 Years After the Discovery of the HIV Virus

30 Nov 2021 06:05:00 By Nasdaq GlobeNewswire

OraSure Technologies to Present at Upcoming Investor Conferences

19 Nov 2021 06:05:00 By Nasdaq GlobeNewswire

OraSure Technologies Announces the Retirement of Jack E. Jerrett and Appointment of Agnieszka M. Gallagher as General Counsel, Chief Compliance Officer and Secretary

09 Nov 2021 06:05:00 By Nasdaq GlobeNewswire

OraSure Technologies Appoints Two New Members to the Board of Directors

08 Nov 2021 06:05:00 By Nasdaq GlobeNewswire

OraSure Technologies Reports 3Q21 Revenue of $53.9 Million, Signs Three Major U.S. Government Contracts Positioning the Company for Significant InteliSwab™ Growth in FY22

03 Nov 2021 15:05:02 By Nasdaq GlobeNewswire

U.S. FDA Authorizes InteliSwab™ COVID-19 Rapid Tests for OTC Single-Use, At-Home Testing for Symptomatic People and Accepts Data for Delta Variant Detection

02 Nov 2021 06:05:00 By Nasdaq GlobeNewswire

OraSure Technologies 2021 Third Quarter Earnings Conference Call Wednesday, November 3, 2021, 5:00 p.m. ET

27 Oct 2021 06:05:00 By Nasdaq GlobeNewswire

OraSure Awarded $109 Million Contract from U.S. Department of Defense to Ramp Manufacturing of InteliSwab™ COVID-19 Rapid Test

04 Oct 2021 06:05:00 By Nasdaq GlobeNewswire

OraSure to Receive up to $13.6 Million from Biomedical Advanced Research Development Authority to Support InteliSwab™ COVID-19 Rapid Test 510(k) Clearance and CLIA Waiver

23 Sep 2021 07:10:00 By Nasdaq GlobeNewswire

OraSure Receives $205 Million Procurement Contract for InteliSwab™ from the Defense Logistics Agency to Supply Over-the-Counter (OTC) Kits as Part of National Pandemic Response

20 Sep 2021 05:00:00 By Nasdaq GlobeNewswire

OraSure Technologies Announces Resignation of CFO Roberto Cuca and Succession Plan

02 Sep 2021 06:00:01 By Nasdaq GlobeNewswire